Celsion Corp represents innovation, dedication, and a commitment to improving patient outcomes. With a focus on developing transformative oncology therapies, the company aims to revolutionize cancer treatment. Celsion's corporate philosophy revolves around collaboration, scientific excellence, and patient-centricity. By leveraging its extensive expertise and advanced technologies, Celsion Corp strives to deliver cutting-edge solutions that address unmet medical needs. With a strong emphasis on research and development, the company continuously seeks breakthroughs in cancer therapies to provide hope and improve the lives of those affected by this devastating disease.

Celsion Corp is primarily present in the United States of America.

Celsion Corp has achieved significant milestones in its journey. The company successfully developed ThermoDox, a novel drug candidate for localized heat-activated chemotherapy. Celsion Corp received Fast Track Designation from the U.S. FDA for ThermoDox and completed Phase III clinical trials, demonstrating promising results in patients with hepatocellular carcinoma. Furthermore, the company successfully presented positive data at renowned medical conferences, gaining recognition for its innovative technology. Celsion Corp's milestones highlight its dedication to advancing cancer treatments and its commitment to improving patient outcomes.

Celsion Corp is a pharmaceutical company established in 1982 and headquartered in Lawrenceville, New Jersey. The company focuses on the development of innovative oncology treatments. Throughout its history, Celsion Corp has conducted extensive research and amassed substantial expertise in the field of heat-activated therapies for cancer treatment. They have a strong commitment to improving patient outcomes and revolutionizing cancer therapies. With a diverse pipeline of promising drug candidates and strategic partnerships, Celsion Corp continues to strive towards breakthrough advancements in oncology.

The main competitors of Celsion Corp in the market include companies such as Biovaxys Technology Corp, KD Pharma Group, NewLink Genetics Corporation, and Therma Bright Inc. These companies operate in the same sector as Celsion Corp and offer similar products and services. However, Celsion Corp distinguishes itself through its innovative approach, extensive research and development efforts, and strategic partnerships. By continuously striving for advancements in the field, Celsion Corp remains competitive in the market and aims to provide unique solutions that cater to the needs of patients and healthcare providers.

Celsion Corp is primarily active in the biotechnology and pharmaceutical industries.

The business model of Celsion Corp is focused on developing and commercializing innovative oncology treatments. The company primarily specializes in heat-activated drug delivery systems and utilizes its proprietary technology, ThermoDox®, to target and deliver chemotherapeutic agents directly to tumors. By using localized heat via radiofrequency ablation or high-intensity focused ultrasound, ThermoDox® enables targeted drug release and enhances the effectiveness of chemotherapy while minimizing side effects. Through strategic collaborations and clinical trials, Celsion Corp aims to provide effective and safer treatment options for patients fighting various forms of cancer.

Det Celsion P/E-forhold er -0,55.

Celsion KUV er 42,13.

AlleAktien Kvalitetsscore for Celsion er 3/10.

Den forventede Celsion omsætning er 255.000,00 USD.

Den forventede Celsion indtjening er -19,41 mio. USD.

Celsion Corp is a biotechnology company specialized in the development and commercialization of cancer treatments. The company focuses on providing state-of-the-art therapies aimed at treating malignant tumors and improving the lives of cancer patients. Celsion operates through a versatile business model, offering a range of products and services. The company has an advanced research and development team dedicated to developing new treatment approaches. One of these product approaches is the so-called ThermoDox®, which inhibits the growth of cancer cells due to temperature changes. Celsion also collaborates closely with research institutions and clinics to test its solutions on cancer patients. This collaboration allows the company to receive feedback from professionals and patients, and improve the effectiveness of its therapies. Another important segment of the company is providing services to other companies, such as support in the research and development of new therapy concepts. The company also offers manufacturing and marketing of drugs and other cancer prevention treatments. Celsion's research and development efforts are focused on the use of nanotechnology, aiming to target cancer cells with new therapy concepts. This research field is highly promising and further advancements are expected in the future. Celsion has tailored its business model to the needs of cancer patients and the industry, aiming to improve the lives of people and clinical outcomes in this field. The company aims to work as a long-term partner for clinics and other companies, and collaboration and provision of products and services in this field also increase the company's growth potential. In conclusion, Celsion Corp is a biotechnology company with a versatile business model that offers therapies and services for cancer patients. The company works in the field of cancer research and development to offer innovative treatment approaches. Additionally, Celsion also provides services to other companies to support the manufacturing and marketing of drugs in the field of cancer prevention. Through collaboration of research, development, and production, the potential in this field is further realized.

Celsion udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Celsion, eller selskabet udbetaler ikke udbytte.

ISIN'en for Celsion er US15117N5032.

WKN for Celsion er A2DQRG.

Tickeren for Celsion er CLSN.

I løbet af de sidste 12 måneder betalte Celsion en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Celsion sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Celsion er i øjeblikket .

Celsion betaler kvartalsvis udbytte. Dette uddeles i månederne .

Celsion betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Celsion bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Celsion fra den 22.7.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 22.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 22.7.2024.

I løbet af 2023 udbetalte Celsion 0 USD i form af dividender.

Udbytterne fra Celsion udbetales i USD.